Research In Brief
This article was originally published in The Gray Sheet
VNS postmarket study: Multicenter, double-blind randomized dosing study (D-21) showed that at 50 weeks, treatment with Cyberonics' VNS Therapy vagus nerve stimulation system improved overall depression symptoms by 32.4%-42%, based on the Montgomery-Asberg Depression Rating Scale, the firm reports May 27. The study was a condition of FDA approval in 2005 for patients with chronic and recurrent treatment-resistant depression (1"The Gray Sheet" July 25, 2005). D-21 compared adjunctive VNS Therapy administered at three stimulation levels (low, medium or high) in 331 patients for 22 weeks. Patients receiving high stimulation did not show significantly greater improvement than those receiving low or medium stimulation at the end of the 22-week acute phase. The study design allowed patients in low and medium groups to receive increased levels of stimulation after 22 weeks
You may also be interested in...
Cyberonics predicts reimbursement for VNS Therapy for treatment-resistant depression (TRD) will be fully secured by 2007, despite encountering protracted difficulties in gaining FDA approval
Purell Battling Class Actions Over Disease Claims While World Scrambles To Increase Hand Sanitizer Supplies
Leading chemical firms, beauty and consumer health companies, even distilleries and medical marijuana cultivators are adapting operations to meet global demand for hand sanitizers amid the COVID-19 pandemic. Meanwhile, plaintiff’s attorneys are busy with multiple class actions against Purell manufacturer GOJO Industries for alleged false advertising following a January warning letter to the firm from the US FDA.
FDA's Emergency Use Authorization for Malaria Drugs Could Hinder Trials of Other COVID-19 Treatments
Questions linger about the role the White House played in pushing the EUA, which comes with large product donations from Bayer and Sandoz that are expected to alleviate supply chain pressures for the drugs.